Enliven Therapeutics, Inc. · NASDAQ:ELVN

Fairmount Funds Management LLC's stake in Enliven Therapeutics, Inc. fell to 3.10% (Schedule 13G/A)

Event Mar 31, 2026 · Filed May 15, 2026

Fairmount Funds Management LLC's stake in Enliven Therapeutics, Inc. fell to 3.10%, 1,855,644 shares, as a passive investor on Mar 31, 2026. Filed May 15, 2026 (Schedule 13G/A).

Stake
3.10%
Shares
1,855,644
Intent
Passive
What changed
Fell below 5%
Filed together
4 holders

The filing in full

HolderStakeShares
Fairmount Funds Management LLC3.10%1,855,644
Fairmount Healthcare Fund II L.P.3.10%1,855,644
Peter Harwin3.10%1,855,644
Kiselak Tomas3.10%1,855,644

Source

View original at SEC

Related